| Outcome . | N of studies available . | N of patients available (%) . | Results (%) . | Missing data . | |
|---|---|---|---|---|---|
| N of studies (%) . | N of patients (%) . | ||||
| Complete remission | 33/45 (73) | 236/368 (64) | 126/236 (53) | 12/45 (27) | 132/368 (36) |
| CR not defined | 52/126 (22) | ||||
| CR according to ACR criteria | 55/126 (23) | ||||
| CR defined by authors | 19/126 (8) | ||||
| Partial remission | 27/45 (60) | 156/368 (42) | 56/156 (36) | 18/45 (40) | 212/368 (58) |
| PR not defined | 19/56 (12) | ||||
| PR according to ACR criteria | 26/56 (17) | ||||
| PR defined by the authors | 11/56 (7) | ||||
| Mortality | 35/45 (78) | 158/368 (43) | 2/158 (1) | 10/45 (22) | 210/368 (57) |
| Steroid reduction ≤7.5 mg/day | 26/45 (58) | 129/368 (35) | 73/129 (57) | 19/45 (42) | 239/368 (65) |
| Relapse | 37/45 (82) | 187/368 (51) | 37/187 (20) | 8/45 (18) | 181/368 (49) |
| Outcome . | N of studies available . | N of patients available (%) . | Results (%) . | Missing data . | |
|---|---|---|---|---|---|
| N of studies (%) . | N of patients (%) . | ||||
| Complete remission | 33/45 (73) | 236/368 (64) | 126/236 (53) | 12/45 (27) | 132/368 (36) |
| CR not defined | 52/126 (22) | ||||
| CR according to ACR criteria | 55/126 (23) | ||||
| CR defined by authors | 19/126 (8) | ||||
| Partial remission | 27/45 (60) | 156/368 (42) | 56/156 (36) | 18/45 (40) | 212/368 (58) |
| PR not defined | 19/56 (12) | ||||
| PR according to ACR criteria | 26/56 (17) | ||||
| PR defined by the authors | 11/56 (7) | ||||
| Mortality | 35/45 (78) | 158/368 (43) | 2/158 (1) | 10/45 (22) | 210/368 (57) |
| Steroid reduction ≤7.5 mg/day | 26/45 (58) | 129/368 (35) | 73/129 (57) | 19/45 (42) | 239/368 (65) |
| Relapse | 37/45 (82) | 187/368 (51) | 37/187 (20) | 8/45 (18) | 181/368 (49) |
EGPA: eosinophilic granulomatosis with polyangiitis; CR: complete response; PR: partial response.
| Outcome . | N of studies available . | N of patients available (%) . | Results (%) . | Missing data . | |
|---|---|---|---|---|---|
| N of studies (%) . | N of patients (%) . | ||||
| Complete remission | 33/45 (73) | 236/368 (64) | 126/236 (53) | 12/45 (27) | 132/368 (36) |
| CR not defined | 52/126 (22) | ||||
| CR according to ACR criteria | 55/126 (23) | ||||
| CR defined by authors | 19/126 (8) | ||||
| Partial remission | 27/45 (60) | 156/368 (42) | 56/156 (36) | 18/45 (40) | 212/368 (58) |
| PR not defined | 19/56 (12) | ||||
| PR according to ACR criteria | 26/56 (17) | ||||
| PR defined by the authors | 11/56 (7) | ||||
| Mortality | 35/45 (78) | 158/368 (43) | 2/158 (1) | 10/45 (22) | 210/368 (57) |
| Steroid reduction ≤7.5 mg/day | 26/45 (58) | 129/368 (35) | 73/129 (57) | 19/45 (42) | 239/368 (65) |
| Relapse | 37/45 (82) | 187/368 (51) | 37/187 (20) | 8/45 (18) | 181/368 (49) |
| Outcome . | N of studies available . | N of patients available (%) . | Results (%) . | Missing data . | |
|---|---|---|---|---|---|
| N of studies (%) . | N of patients (%) . | ||||
| Complete remission | 33/45 (73) | 236/368 (64) | 126/236 (53) | 12/45 (27) | 132/368 (36) |
| CR not defined | 52/126 (22) | ||||
| CR according to ACR criteria | 55/126 (23) | ||||
| CR defined by authors | 19/126 (8) | ||||
| Partial remission | 27/45 (60) | 156/368 (42) | 56/156 (36) | 18/45 (40) | 212/368 (58) |
| PR not defined | 19/56 (12) | ||||
| PR according to ACR criteria | 26/56 (17) | ||||
| PR defined by the authors | 11/56 (7) | ||||
| Mortality | 35/45 (78) | 158/368 (43) | 2/158 (1) | 10/45 (22) | 210/368 (57) |
| Steroid reduction ≤7.5 mg/day | 26/45 (58) | 129/368 (35) | 73/129 (57) | 19/45 (42) | 239/368 (65) |
| Relapse | 37/45 (82) | 187/368 (51) | 37/187 (20) | 8/45 (18) | 181/368 (49) |
EGPA: eosinophilic granulomatosis with polyangiitis; CR: complete response; PR: partial response.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
